• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

2015-2019 年商业健康保险计划中处方药制造商回扣的趋势。

Trends of Prescription Drug Manufacturer Rebates in Commercial Health Insurance Plans, 2015-2019.

机构信息

Neeley School of Business, Texas Christian University, Fort Worth.

TCU School of Medicine, Texas Christian University, Fort Worth.

出版信息

JAMA Health Forum. 2022 May 6;3(5):e220888. doi: 10.1001/jamahealthforum.2022.0888. eCollection 2022 May.

DOI:10.1001/jamahealthforum.2022.0888
PMID:35977258
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9077484/
Abstract

This economic evaluation examines the magnitude and trend of prescription drug rebates in commercial markets from 2015 to 2019 and identifies insurance plan factors associated with rebates.

摘要

本经济评估考察了 2015 年至 2019 年商业市场处方药回扣的规模和趋势，并确定了与回扣相关的保险计划因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff7b/9077484/d3675d65f52f/jamahealthforum-e220888-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff7b/9077484/d3675d65f52f/jamahealthforum-e220888-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff7b/9077484/d3675d65f52f/jamahealthforum-e220888-g001.jpg

相似文献

1
Trends of Prescription Drug Manufacturer Rebates in Commercial Health Insurance Plans, 2015-2019.2015-2019 年商业健康保险计划中处方药制造商回扣的趋势。
JAMA Health Forum. 2022 May 6;3(5):e220888. doi: 10.1001/jamahealthforum.2022.0888. eCollection 2022 May.
2
Association of Branded Prescription Drug Rebate Size and Patient Out-of-Pocket Costs in a Nationally Representative Sample, 2007-2018.2007-2018 年，全国代表性样本中品牌处方药回扣规模与患者自付费用的关联。
JAMA Netw Open. 2021 Jun 1;4(6):e2113393. doi: 10.1001/jamanetworkopen.2021.13393.
3
Inflationary Rebates For Generic Drugs Sold Through Medicaid Saved Billions During 2017-20.2017 年至 2020 年期间，通过医疗补助计划销售的仿制药的通胀回扣节省了数十亿美元。
Health Aff (Millwood). 2023 Jun;42(6):770-778. doi: 10.1377/hlthaff.2022.01029.
4
Correlation Between Changes in Brand-Name Drug Prices and Patient Out-of-Pocket Costs.品牌药价格变化与患者自付费用的相关性。
JAMA Netw Open. 2021 May 3;4(5):e218816. doi: 10.1001/jamanetworkopen.2021.8816.
5
Comparison of Out-of-Pocket Spending on Ultra-Expensive Drugs in Medicare Part D vs Commercial Insurance.医疗保险部分 D 与商业保险中超昂贵药物自付费用比较。
JAMA Health Forum. 2023 May 5;4(5):e231090. doi: 10.1001/jamahealthforum.2023.1090.
6
Association of Prescription Drug Price Rebates in Medicare Part D With Patient Out-of-Pocket and Federal Spending.医疗保险D部分处方药价格回扣与患者自付费用及联邦支出的关联
JAMA Intern Med. 2017 Aug 1;177(8):1185-1188. doi: 10.1001/jamainternmed.2017.1885.
7
What Determines How Much Your Patient Pays for Their Medication in the United States?在美国，是什么决定了你的患者为其药物支付多少费用？
Am J Ophthalmol. 2016 Jul;167:48-51. doi: 10.1016/j.ajo.2016.04.010. Epub 2016 Apr 27.
8
Association of Drug Rebates and Competition With Out-of-Pocket Coinsurance in Medicare Part D, 2014 to 2018.2014 年至 2018 年期间，医疗保险处方药部分的药品回扣和竞争与自付共付额的关系。
JAMA Netw Open. 2021 May 3;4(5):e219030. doi: 10.1001/jamanetworkopen.2021.9030.
9
The Impact of Job and Insurance Loss on Prescription Drug use: A Panel Data Approach to Quantifying the Health Consequences of Unemployment During the Covid-19 Pandemic.工作和保险损失对处方药使用的影响：一种定量分析新冠疫情期间失业对健康影响的面板数据方法。
Int J Health Serv. 2022 Jul;52(3):312-322. doi: 10.1177/00207314221078749. Epub 2022 Feb 15.
10
Prior Authorization, Copayments, and Utilization of Sacubitril/Valsartan in Medicare and Commercial Plans in Patients With Heart Failure With Reduced Ejection Fraction.心力衰竭伴射血分数降低患者在医疗保险和商业计划中使用沙库巴曲缬沙坦的预先授权、共同支付和利用情况。
Circ Cardiovasc Qual Outcomes. 2021 Sep;14(9):e007665. doi: 10.1161/CIRCOUTCOMES.120.007665. Epub 2021 Sep 1.

引用本文的文献

1
Cost-Effectiveness of Bempedoic Acid in High Cardiovascular Risk Patients with Statin Intolerance: An Analysis of the CLEAR Outcomes Trial.贝派地酸在他汀类药物不耐受的高心血管风险患者中的成本效益：CLEAR Outcomes试验分析
Am J Cardiovasc Drugs. 2025 Aug 20. doi: 10.1007/s40256-025-00753-w.
2
Impact of payer rejections and out-of-pocket costs on patient access to bempedoic acid therapy.医保支付方拒付及自付费用对患者使用贝派地酸治疗的影响。
Am J Prev Cardiol. 2025 Feb 8;21:100940. doi: 10.1016/j.ajpc.2025.100940. eCollection 2025 Mar.
3
Estimated Changes in Insulin Prices and Discounts After Entry of New Insulin Products, 2012-2019.

本文引用的文献

1
Estimating Rebates and Other Discounts Received by Medicare Part D.估算医疗保险处方药部分（Medicare Part D）收到的回扣和其他折扣
JAMA Health Forum. 2021 Jun 4;2(6):e210626. doi: 10.1001/jamahealthforum.2021.0626.
2
Association of Branded Prescription Drug Rebate Size and Patient Out-of-Pocket Costs in a Nationally Representative Sample, 2007-2018.2007-2018 年，全国代表性样本中品牌处方药回扣规模与患者自付费用的关联。
JAMA Netw Open. 2021 Jun 1;4(6):e2113393. doi: 10.1001/jamanetworkopen.2021.13393.
3
Changes in List Prices, Net Prices, and Discounts for Branded Drugs in the US, 2007-2018.
2012-2019 年新胰岛素产品上市后胰岛素价格和折扣的估计变化。
JAMA Health Forum. 2023 Jun 2;4(6):e231430. doi: 10.1001/jamahealthforum.2023.1430.
2007-2018 年美国品牌药物的目录价格、净价格和折扣变化。
JAMA. 2020 Mar 3;323(9):854-862. doi: 10.1001/jama.2020.1012.
4
Pharmacy Benefit Managers, Brand-Name Drug Prices, and Patient Cost Sharing.药品福利管理公司、品牌药价格与患者费用分担
Ann Intern Med. 2018 Mar 20;168(6):436-437. doi: 10.7326/M17-2506. Epub 2018 Feb 13.